The potential nephroprotective effects of GLP-1RAs had been reported in a further analysis of renal outcomes in a series of CVOTs trials that showed reduction in proteinuria and hinted at slowing eGFR decline
Together, well agree on a plan for moving forward with treatment
It has gained recognition as an effective weight management medication, especially for those with obesity
Real-World Examples: 250-Pound Person: Average loss: 56 pounds (22.5%) Final weight: 194 pounds Timeline: 18-20 months 200-Pound Person: Average loss: 45 pounds (22.5%) Final weight: 155 pounds Timeline: 18-20 months 300-Pound Person: Average loss: 67 pounds (22.5%) Final weight: 233 pounds Timeline: 20-24 months Dosing Schedule: Standard Escalation: Weeks 1-4: 2.5 mg weekly (starting dose) Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly Weeks 13-16: 10 mg weekly (if tolerating well) Weeks 17-20: 12.5 mg weekly (if needed) Week 21+: 15 mg weekly (maximum dose for weight loss) Flexible Dosing: Not everyone needs maximum 15 mg dose Many achieve excellent results at 10 mg Provider adjusts based on results and tolerance Can stay at effective dose rather than pushing to maximum Side Effects: Most Common: Nausea: 30-37% (lower than semaglutide despite higher potency) Diarrhea: 19-23% Vomiting: 9-17% Constipation: 10-17% Abdominal discomfort: 8-11% Interesting Finding: Despite being more potent, tirzepatide causes less nausea and vomiting than semaglutide
Patients with type two diabetes can take semaglutide (Wegovy, Ozempic, Rybelsus) to lose weight, lower blood sugar levels and reduce the risk of major cardiovascular events such as heart attacks and strokes
Semaglutide is injected weekly and does not require daily coordination
